Toujeo

Toujeo

insulin glargine

Manufacturer:

Sanofi-Aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Insulin glargine
Dosage/Direction for Use
SC Individualized dose. Administer once daily, at anytime during the day, preferably at the same time everyday. May be administered up to 3 hr before or after their usual time of administration. Patients w/ type 1 DM Individualized dose; used once daily w/ meal-time insulin. Patients w/ type 2 DM Initially 0.2 U/kg once daily followed by individual adjustments.
Contraindications
Special Precautions
Not intended for IV or insulin infusion pump administration. Intense monitoring of blood glucose level in patients in whom sequelae of hypoglycemic episodes may be relevant. Monitor change in inj area; increase of insulin sensitivity, unaccustomed, increased or prolonged physical exercise, intercurrent illness, inadequate food intake, alcohol consumption, uncompensated endocrine disorders, concomitant use w/ certain medications. Correct hypoglycemia by immediate carbohydrate intake. Switching between insulin glargine, & insulins & Toujeo. Maintain carbohydrate supplies in patients w/ type 1 diabetes. Insulin antibodies may form. Concomitant use w/ pioglitazone. Discontinue if any deterioration in cardiac symptoms occurs. Ability to concentrate & react may be impaired. Pregnancy & lactation. Ped patients ≤18 yr. Elderly. Renal & hepatic impairment.
Adverse Reactions
Hypoglycemia; retinopathy; lipodystrophy; skin allergic reactions at inj site; redness, pain, swelling, itching, hives, inflammation.
Drug Interactions
Blood glucose-lowering effect may be increased by anti-hyperglycaemic drugs, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates, sulfonamide antibiotics. Blood glucose-lowering effect may be reduced by corticosteroids, danazol, diazoxide, diuretics, sympathomimetics (eg, epinephrine, salbutamol, terbutaline); glucagon, INH, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (eg, OCs); PIs & atypical antipsychotics (eg, olanzapine & clozapine). Blood glucose-lowering effect may either be potentiated or weakened by β-blockers, clonidine, lithium salts & alcohol. Hypoglycemia then hypergylcemia may occur w/ pentamidine. Reduced or absence of adrenergic counter regulation w/ β-blockers, clonidine, guanethidine & reserpine.
ATC Classification
A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Presentation/Packing
Form
Toujeo Soln for inj 300 U/mL
Packing/Price
1.5 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in